Chinese biopharmaceutical company CANbridge Life Sciences has raised US$25 million in a series B round from lead investor Lapam Capital, a Beijing-based life science venture capital firm.
Existing investor Qiming Venture Partners and new investors, Yuanming Capital, Yanyuan Capital, Biossom Investment Management and Wuxi App Tec, also participated in the round, the company announced today.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription? Log in
